An investigational triple-hormone-receptor drug from Eli Lilly, in late-stage trials for weight loss, blood sugar, liver fat and joint pain — with some of the largest reported effect sizes in its class.
What is it?An investigational injectable peptide from Eli Lilly that activates three hormone receptors at once — GLP-1, GIP and glucagon — instead of the one or two targeted by earlier drugs like Ozempic or Zepbound.23
Why are people interested?Mostly weight loss: Phase 3 trials have reported some of the largest reductions seen for an outpatient drug, plus effects on blood sugar, liver fat and knee pain.24
Human researchExtensive and growing — a peer-reviewed Phase 2 program plus at least eight Phase 3 studies, several already reported (so far only as company announcements, not yet peer-reviewed publications).723
Development & approval statusInvestigational only. Not approved anywhere in the world; Lilly has said it plans to file for FDA approval in early 2027.317
Supply outside clinical trialsA large market in unapproved, unregulated product has grown up ahead of approval — covered in detail under Safety, Regulatory Status and Quality, below.2122
What Are People Interested in Retatrutide For?
Weight Loss
Evidence: Strong Human Evidence
What the Research Says
Weight loss is the headline finding across retatrutide's entire trial program. The original Phase 2 trial (Jastreboff et al., published in the New England Journal of Medicine, 2023; n=338) reported 24.2% average weight loss at 48 weeks on the 12 mg dose, with the weight-loss curve still descending at the end of the study.23 Company-announced (not yet peer-reviewed) results from five Phase 3 trials have since reported even larger numbers: in TRIUMPH-1 — 2,339 adults with obesity, 80 weeks — the 12 mg dose produced 28.3% average weight loss versus about 2% on placebo.24 Lower doses still delivered substantial results: the 4 mg dose, reached with only one dose-escalation step, produced 19.0% average loss.2
What the Real World Says
Weight loss is the reason almost everyone seeks retatrutide out, well ahead of any FDA approval. People commonly use it for:
More aggressive weight loss than approved GLP-1 drugs are seen to deliver
Switching from tirzepatide (Zepbound/Mounjaro) after a weak response, side effects, or cost and access problems
General interest in the "next generation" of GLP-1-class drugs
One documented finding is worth stating plainly: people using non-trial retatrutide lost meaningfully less weight than participants in the actual clinical trials.21
See the ResearchStudies, numbers and limits
Phase 3 results (company-announced, not yet peer-reviewed)
TRIUMPH-1 (obesity, n=2,339, 80 weeks): 9 mg and 12 mg doses produced 25.9% and 28.3% average weight loss respectively, versus 2.2% on placebo; ≥30% weight loss — a threshold long associated with bariatric surgery — was reached by 45.3% of people on 12 mg.2
TRIUMPH-2 (obesity with type 2 diabetes, n=1,152, 80 weeks): up to 20.8% weight loss on the 12 mg dose.3
TRIUMPH-3 (obesity with cardiovascular disease, n=1,949, 80 weeks): up to 22.6% weight loss on 12 mg, with major cardiovascular events occurring less often than expected in both the retatrutide and placebo groups.3
The peer-reviewed foundation
The Phase 2 obesity trial (Jastreboff et al., NEJM 2023; n=338) is, as of this build, the main peer-reviewed human efficacy data for retatrutide — the Phase 3 program above exists so far only as Lilly's own topline announcements and secondary press coverage of them, not as published, peer-reviewed papers.23
Limitations
Every trial to date has been funded by Eli Lilly, the drug's developer.23
The Phase 3 headline numbers above have not yet gone through peer review; company-announced topline results can change or be qualified once full data is published.23
The longest published data currently runs to 80 weeks.2
Type 2 Diabetes & Blood Sugar
Evidence: Strong Human Evidence
What the Research Says
In company-announced results from TRANSCEND-T2D-1, a 40-week Phase 3 trial in adults with type 2 diabetes, people on the 12 mg dose lost 16.8% of body weight alongside meaningful A1C reductions.14 TRIUMPH-2, a larger 80-week Phase 3 trial in people with both obesity and type 2 diabetes, similarly announced A1C reductions of up to 1.6 percentage points from a baseline around 7.7%, alongside more than 20% weight loss on higher doses.3 Neither trial's full results have been published in a peer-reviewed journal as of this build.
What the Real World Says
People managing diabetes discuss retatrutide far less than the general weight-loss crowd, and reporting rarely separates them out as a distinct group.21
See the ResearchStudies, numbers and limits
In TRANSCEND-T2D-1, A1C reductions reached up to roughly 1.9 percentage points at the 12 mg dose, reported together with weight loss rather than as an isolated effect.4
In TRIUMPH-2, A1C fell by 1.4 to 1.6 percentage points across the 4 mg, 9 mg and 12 mg doses, compared with 0.2 points on placebo.3
Liver Fat (MASLD)
Evidence: Strong Human Evidence
What the Research Says
This is retatrutide's one major peer-reviewed efficacy finding beyond the core Phase 2 obesity trial. In a placebo-controlled substudy published in Nature Medicine (Sanyal et al.) — 98 people with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called fatty liver disease) — the two higher doses of retatrutide reduced liver fat by 81–86% at 48 weeks, compared with under 5% for placebo, and most participants on those doses no longer met the threshold for MASLD by the end of the study.181920 This is a Phase 2 substudy in a relatively small group, not yet confirmed in a dedicated Phase 3 MASLD trial, and retatrutide is not approved to treat liver disease.18
What the Real World Says
Liver fat isn't something people notice on their own, so it's rarely why someone seeks retatrutide out — when it comes up, it's treated as a bonus of weight loss, not the main goal.21
See the ResearchStudies, numbers and limits
By week 24, relative liver fat reduction reached 81.4% and 82.4% on the 8 mg and 12 mg doses versus 0.3% on placebo (p<0.001 for all retatrutide doses versus placebo); benefits were sustained through week 48.1819
Between 79% and 93% of people on the 8 mg and 12 mg doses reached 'normal' liver fat levels (under 5%) by week 48.1920
The substudy population was relatively small (98 people), mostly from the US, and didn't include people with more advanced liver scarring — larger and longer studies would be needed before this becomes a treatment for liver disease specifically.20
Knee Osteoarthritis Pain
Evidence: Strong Human Evidence
What the Research Says
TRIUMPH-4, a 68-week Phase 3 trial in 445 adults with obesity and knee osteoarthritis, was the first Phase 3 readout for retatrutide, announced by Lilly and covered by trade press; full peer-reviewed results aren't published yet.54 Participants on the 12 mg dose lost 28.7% of body weight and reported roughly a 75% reduction in WOMAC pain scores, a far larger improvement than on placebo.54 The trial wasn't designed to fully separate a direct effect on joint pain from the effect of losing a large amount of weight, which is itself known to reduce knee osteoarthritis pain.5
What the Real World Says
This is a newer, less-established interest — people don't yet clearly separate "my knees feel better" from the general relief that comes with major weight loss.21
See the ResearchStudies, numbers and limits
WOMAC pain scores fell by up to 4.5 points from a baseline around 6, a roughly 76% relative reduction; more than 1 in 8 participants on retatrutide reported being completely pain-free by the end of the trial.5
Other Areas People Talk About
Sleep Apnea
Research: In a subgroup of 243 people with moderate-to-severe obstructive sleep apnea followed in TRIUMPH-1 (company-announced results), breathing interruptions fell by up to roughly 36 events per hour at 80 weeks.20
Heart & Metabolic Markers
Research: The peer-reviewed Phase 2 trial found consistent improvements in blood pressure, triglycerides and LDL cholesterol alongside weight loss; roughly 30–40% of people on higher doses stopped at least one blood-pressure medication during the study.23 Across the program, retatrutide also produces a small, consistent rise in resting heart rate — roughly 3–4 beats per minute above placebo — a class effect linked to GLP-1 receptor activity on the heart's pacemaker cells.21
Real World: A large real-world study found people using retatrutide reported more new heart-related symptoms than similar patients on approved GLP-1 drugs — a real signal worth knowing about. See Safety, below, for the important context around it.21
Retatrutide in the Real World: The Practical Questions
Straight answers to the questions people ask most: amounts discussed online, starting low, results, side effects, switching, duration and stacking. Expand any topic to compare community practice with clinical research.
The short version: Community discussions often focus on 0.5–4 mg weekly, with some reporting an effect at 1–4 mg. A low starting amount and gradual increases are recurring themes because nausea and other digestive effects can become more troublesome when the amount rises. These are patterns in selected online discussions—not measured population averages or an established retatrutide dosing schedule. In the published obesity trial, escalation occurred at four-week intervals, not weekly. See the study.
Amounts & starting lowWhat people discuss, and what the trial actually tested▸
🌎 Real World Says
Common discussion: Lower-dose users frequently describe starting around 0.5 mg weekly and discussing 1–4 mg as a range where they notice appetite or weight effects. Some discuss 0.5 mg increases, but the pace varies: posts describe holding a level for several weeks rather than increasing automatically each week. These reports do not establish that most users respond in this range, or that 0.5 mg weekly increases are safe or effective.262833
Practical takeaway: A recurring message in the discussions is to avoid escalating simply because a higher amount exists. More is not automatically better, particularly when appetite suppression already makes eating difficult.
🔬 Research Says
The 2023 peer-reviewed Phase 2 trial randomized 338 adults to 1, 4, 8 or 12 mg once weekly (with different initial doses). People assigned 4 mg or more began at either 2 or 4 mg, with escalation at four-week intervals, under trial supervision. This is a description of the study, not an individual dosing plan.25
Assigned weekly dose
Mean weight loss, week 24
Mean weight loss, week 48
1 mg
7.2%
8.7%
4 mg, combined arms
12.9%
17.1%
8 mg, combined arms
17.3%
22.8%
12 mg
17.5%
24.2%
Placebo
1.6%
2.1%
These are trial-group averages, not a prediction for an individual. The 4 mg and 8 mg rows combine different starting-dose groups.25
Timing, splitting & switchingWeekly use, changing from tirzepatide, and overlapping drugs▸
🌎 Real World Says
What is discussed: Once-weekly use is common. Some users discuss splitting their weekly amount to try to smooth effects, but accounts also describe nausea and fatigue despite splitting. People switching from tirzepatide report very different experiences: some notice renewed appetite control, while others describe hunger returning or little initial effect. There is no reliable conversion chart between the drugs.293032
Practical takeaway: Prior tolerance of tirzepatide does not establish tolerance of retatrutide. Overlapping the two is described online but has not been validated for safety or benefit.31
🔬 Research Says
Retatrutide's obesity trials used once-weekly subcutaneous administration. The peer-reviewed Phase 2 study did not test splitting the weekly amount, switching equivalencies from semaglutide/tirzepatide, or overlapping incretin drugs.25
There is no validated milligram-for-milligram conversion between these different molecules. Retatrutide also acts on the glucagon receptor, so its effects cannot be inferred simply from the amount of tirzepatide previously used.
Results & plateausWhat people notice first and why the scale may stall▸
🌎 Real World Says
Common themes: Appetite and fullness are often the first changes people discuss; weight changes can follow over weeks. Reports also describe delayed effects, plateaus after initial loss and frustration when a higher amount causes nausea without a corresponding improvement in weight loss. A plateau alone cannot establish that the compound has stopped working.262729
Practical takeaway: Online accounts suggest the experience is not a straight line. Published trials measured weight loss over months, not an expectation of weekly scale movement.
🔬 Research Says
In Phase 2, the 24-week weight-loss averages were 7.2%, 12.9%, 17.3% and 17.5% for the 1, 4, 8 and 12 mg groups. At 48 weeks, those averages were 8.7%, 17.1%, 22.8% and 24.2%. The study was designed to assess these two milestones, not to guarantee early weekly losses or a plateau-free trajectory.25
Existing company-announced Phase 3 findings in the page extend follow-up to 80 weeks; they should remain visibly distinguished from peer-reviewed publications.2
Side effects & escalationWhy the low-and-slow theme comes up so often▸
🌎 Real World Says
Commonly discussed: Nausea, early fullness, constipation, diarrhea and occasional vomiting. Skin sensitivity and fatigue also appear in discussions. A recurring pattern is feeling fine at a lower amount, then experiencing markedly worse digestive symptoms after an increase. Some accounts describe symptoms even with relatively small changes, so gradual escalation does not eliminate risk.28323334
Practical takeaway: The broader lesson from both online reports and trials is that tolerability matters more than reaching a number quickly. Severe abdominal pain, repeated vomiting, dehydration symptoms or a sustained racing heartbeat are not ordinary adjustment effects to ignore.
🔬 Research Says
The peer-reviewed Phase 2 trial reported nausea in 27%, diarrhea in 13%, vomiting in 10%, constipation in 9% and fatigue in 7% of retatrutide-treated participants overall. Nausea ranged from 14% in the 1 mg group to 60% in one 8 mg group with a 4 mg initial dose; the 12 mg group reported 45%. Skin sensitivity/hyperesthesia was reported in 7% versus 1% on placebo. Adverse events led to discontinuation in 6–16% of retatrutide arms, versus none in the placebo arm.25
Heart rate rose in a dose-dependent pattern to week 24, then declined. Persistent vomiting, inability to keep fluids down, severe abdominal pain, fainting or a sustained racing heartbeat merit prompt clinical assessment rather than waiting for an online reassurance.
Duration, maintenance & stoppingWhy there is no established short cycle▸
🌎 Real World Says
What is discussed: People commonly talk about remaining at an amount while appetite and weight are responding, rather than escalating at every opportunity. Others discuss lowering or stopping when eating becomes difficult, or when side effects outweigh perceived benefits. Hunger returning after discontinuing another incretin drug also appears in switching discussions.2730
Practical takeaway: There is no verified community-wide maintenance amount, standard cycle or evidence-based off-cycle. Individual reports cannot tell us what happens after long-term non-trial use.
🔬 Research Says
The published Phase 2 obesity trial treated participants for 48 weeks followed by a four-week safety follow-up. The 80-week Phase 3 results summarized elsewhere on this page are company announcements, not a tested maintenance protocol for community users.252
Neither a standard off-cycle nor a validated maintenance strategy for non-trial retatrutide has been established.
Stacking & preserving muscleSeparating popular combinations from established benefits▸
🌎 Real World Says
What is discussed: Overlapping retatrutide with tirzepatide during a switch and adding other peptides for body composition both come up online. Neither practice has an established benefit or safety profile. Another recurring concern is appetite suppression so strong that eating sufficient protein or maintaining strength training becomes difficult.2631
Practical takeaway: Weight loss is not the same as fat loss. A lower number on the scale cannot by itself show how much muscle someone retained.
🔬 Research Says
Retatrutide activates GLP-1, GIP and glucagon receptors; tirzepatide activates GLP-1 and GIP, while semaglutide activates GLP-1. These are mechanistic differences, not a milligram-equivalence chart. The published Phase 2 trial does not validate combining retatrutide with tirzepatide, semaglutide or research-peptide stacks.25
Cross-trial weight-loss percentages differ by population, duration and design. Direct head-to-head comparisons should be identified separately from comparisons of unrelated studies.
The distinction
Trial doses and outcomes describe monitored research. Online amounts, switching patterns and stacks describe what people discuss—not tested instructions or reliable estimates of what an unapproved product will do.
How we use community reports: Each example links to the actual post, gives the reported amount and timeframe when available, and includes setbacks as well as positive results. Self-reported doses, product identity, medical history and outcomes are unverified. Trial doses are historical study arms, not a self-treatment schedule.
What About Safety?
What We Know
Gastrointestinal side effects are the most common finding across every trial: in company-announced TRIUMPH-4 results, nausea affected about 43% of people on the 12 mg dose versus 11% on placebo, with diarrhea, vomiting and constipation also elevated and dose-dependent.910 These usually appear during dose escalation and are mild to moderate for most people.10
A preprint analysis of self-reported symptoms among Reddit users of non-trial retatrutide found a somewhat different pattern than the trials: appetite increase, fatigue, increased energy, insomnia and elevated heart rate were described at least as often as nausea. The authors describe this as hypothesis-generating, not a confirmed difference in the drug's actual effects — self-reported, non-random samples like this can't establish true rates.8
Dysesthesia — tingling or altered skin sensation — is a less-common but distinct finding: it affected about 21% of people on the 12 mg dose in Phase 3 results, more than has been reported for other GLP-1-class drugs, and is thought to relate to retatrutide's added glucagon-receptor activity.910
A modest, consistent rise in resting heart rate (roughly 3–4 bpm above placebo) has shown up consistently across the trial program.21
What We Don't Know
Safety beyond the roughly 80-week window covered by the longest reported trials.2
Whether retatrutide carries the same thyroid C-cell tumor warning applied to other GLP-1-class drugs based on animal data — this hasn't been separately established for retatrutide, but regulators are expected to apply the same class-based caution.24
Safety in pregnancy or while breastfeeding, neither of which has been studied.24
Reported / Identified Concerns
Discontinuation due to side effects was higher on retatrutide than on placebo in company-announced Phase 3 results — roughly 4–11% depending on dose, versus about 5% on placebo.9
Regulators have flagged class-related concerns shared across GLP-1/GIP-based drugs — pancreatitis, gallbladder disease, and slowed stomach emptying (relevant around sedation or surgery) — as things to watch for, though none of these have been established as elevated specifically for retatrutide.24
A preprint analysis of health records found people using unapproved, non-trial retatrutide had more new cardiovascular and neuropsychiatric symptoms than comparable patients on approved GLP-1-class drugs, alongside weight loss below what trial participants achieved. This is an observed association from one not-yet-peer-reviewed study; it doesn't by itself establish what caused the difference.21
A separate, independent source describes product testing on non-trial retatrutide finding substantial contamination and identity or potency problems.22 This is a distinct finding from a different source than the health-records study above — the two are related in subject matter (both concern non-trial supply) but were not part of the same research.
Is It Approved or Legal?
Status as of September 2026 — this is an actively developing, investigational drug, and status can change quickly.
United States
Investigational — not approved
In Phase 3 development. Not approved for any use, and cannot legally be compounded — the FDA has said explicitly that retatrutide doesn't meet the requirements under federal compounding law (sections 503A/503B).1213 The FDA has issued warning letters to more than a dozen sellers of unapproved retatrutide products, and Lilly has filed multiple lawsuits against sellers outside its approved trial and distribution channels.1115 Lilly has said it plans to file for FDA approval in early 2027.3
Canada
Not authorized
Not approved for human use by Health Canada. Lilly Canada has publicly stated that unapproved retatrutide is being sold online and through social media without regulatory authorization, describing what's sold this way as not a regulated medicine.15
Worldwide
Not approved anywhere
As of this writing, no regulator anywhere — including the UK's MHRA or Australia's TGA — has approved retatrutide for any use. It remains legally available only to people enrolled in Lilly's clinical trials.1714
Sport / WADA
Not on the Prohibited List
Retatrutide is not on WADA's Prohibited List. Markers for detecting some other GLP-1-class drugs are on WADA's monitoring program, though GLP-1-class agonists generally aren't currently prohibited in sport.16
Retatrutide vs. Tirzepatide
Both are once-weekly injectable incretin drugs from Eli Lilly, and both work partly through the same GLP-1 and GIP receptors. Retatrutide adds a third target, the glucagon receptor, which researchers propose explains its especially strong effect on liver fat and its edge in cross-trial weight-loss comparisons.2318 Tirzepatide (sold as Zepbound and Mounjaro) is FDA-approved and has years of peer-reviewed publication behind it; retatrutide is still investigational, and its Phase 3 results exist so far mainly as company announcements.17
A head-to-head Phase 3 trial, TRIUMPH-5, is comparing the two directly, but as of this build it's listed as active and not yet reporting results.7 Until it reports, most public comparisons rely on separate trials with different populations and designs, which is weaker evidence than a direct comparison — worth treating as suggestive, not conclusive.
What We Still Don't Know
What will the final approved dose and label actually say?
That depends on FDA review of Lilly's submission, expected to begin in 2027 — the label, warnings and approved population could all differ from what's been tested so far.3
What happens after 80 weeks of use?
The longest reported trial data currently runs to 80 weeks. TRIUMPH-Outcomes, a multi-year registered trial in roughly 10,000 participants, is underway to study long-term cardiovascular and kidney outcomes, but hasn't reported results yet.6
Will the Phase 3 topline numbers hold up in peer review?
Company-announced results are usually consistent with the eventual peer-reviewed publication, but details, subgroup findings, and safety tables can shift once the full data is published and independently reviewed. None of the Phase 3 trials above have completed that process yet.235
Does non-trial retatrutide actually match what's used in the clinical trials?
One independent source describes product testing that found meaningful contamination and identity or potency problems in non-trial products — there's no guarantee that what's sold outside the trials as "retatrutide" is retatrutide, at the concentration claimed, or free of contaminants.22
How does it really compare to tirzepatide, head-to-head?
TRIUMPH-5 is running that direct comparison but hasn't reported yet — see Compare, above.7
Is it safe for people with a history of pancreatitis or thyroid cancer, or during pregnancy?
None of these have been specifically studied for retatrutide; regulators are applying the same cautious approach used across the rest of the GLP-1 class.24
Quality Matters Too.
Whether the research supports a compound, and whether a specific product actually contains what its label says, are two separate questions — and for retatrutide, right now, the second question matters a great deal. Nothing sold outside Lilly's clinical trials has gone through the identity, purity, sterility or dose-accuracy checks an approved medicine requires.13
One independent source describes product testing on non-trial retatrutide that found real problems — including contamination and inaccurate labeled concentrations.22 A certificate of analysis, where one even exists, can speak to identity and purity; it can't tell you whether a compound is effective, and it isn't a substitute for regulatory approval.
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes (TRANSCEND-T2D-1 topline results; company announcement, not peer-reviewed).Lilly investor release, Mar 2026
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline results; company announcement, not peer-reviewed).Lilly investor release, May 2026
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (TRIUMPH-2 and TRIUMPH-3 topline results; company announcement, not peer-reviewed).Lilly/PR Newswire, Jul 2026
Phase III retatrutide study demonstrates 30% weight loss (trade-press coverage of company-announced results).The Pharmaceutical Journal
Lilly's Retatrutide Displays Positive Topline Results in Successful Phase III Trial (TRIUMPH-4, knee osteoarthritis; trade-press coverage of company-announced results).Pharmaceutical Executive
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes), NCT06383390 — registered trial, active, results not yet reported.ClinicalTrials.gov
Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker (secondary aggregator; trial-status table, including TRIUMPH-5 head-to-head status — used only for registry/status metadata, cross-checked against ClinicalTrials.gov and Lilly announcements).GLP3.wiki trial tracker
Self-Reported Side Effects Among Reddit Users Taking Nonapproved Retatrutide (medRxiv preprint, not yet peer-reviewed).medRxiv preprint
Retatrutide Phase 3 Results 2026: TRIUMPH Trial Tracker — side effects data (secondary aggregator; cross-checked against Lilly/trade-press figures).GLP3.wiki side effects
Retatrutide Side Effects (secondary summary of trial safety data).Lola Health
Unapproved Retatrutide Use Challenges Clinicians.Medscape
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.U.S. FDA
FDA Warns Companies Over Compounded Retatrutide: What Healthcare Providers Should Know.Lengea Law
Retatrutide Regulatory Status 2026: Provider Fact Check.ScriptLinkRx
Drugmaker warns Canadians about 'unapproved and illegal' obesity medication.CP24
Retatrutide reduces hepatic fat and biomarkers of MASH/fibrosis in a Phase 2 MASLD substudy (Sanyal et al.) — peer-reviewed.Nature Medicine, via PMC
Retatrutide 'wiped out' fat in liver of obese patients (institutional coverage of the peer-reviewed Sanyal et al. substudy).VCU Health
Retatrutide benefits at a glance (secondary summary; liver fat detail table, sleep apnea subgroup data from company-announced TRIUMPH-1 results).Chemist Click
Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms (Murugadoss, Venkatakrishnan & Soundararajan) — preprint, not yet peer-reviewed.Preprints.org (nference)
Retatrutide report — independent commentary citing product-testing data on non-trial supply (contamination, identity/potency); a separate source from ref. 21, not part of the same study.Outliyr
Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide — coverage of Jastreboff et al., NEJM 2023, the peer-reviewed Phase 2 trial.TCTMD
Is retatrutide safe? — class-level warnings on pancreatitis, thyroid cancer history, gallbladder disease and gastroparesis.Chemist Click
Peptide research can get complicated quickly. If you'd rather talk it through with someone who can help you understand the terminology, research and questions worth asking:
